Sodium butyrate entrapped chitosan-PAMAM for suppression of colorectal cancer cells

Basit Öğe Kaydı
dc.contributor.authorAl-Zihaymee, Ruaa Mahdi Mayih
dc.contributor.authorMohammadnejad, Javad
dc.contributor.authorNarmani, Asghar
dc.contributor.authorJafar, Hanieh
dc.contributor.authorOzbolat, Guluzar
dc.contributor.authorDaemi, Amin
dc.contributor.authorDogus, Yusuf
dc.date.accessioned2026-04-25T14:20:17Z
dc.date.available2026-04-25T14:20:17Z
dc.date.issued2025
dc.departmentSinop Üniversitesi
dc.description.abstractObjective Cancer treatment is a major concern of health worldwide. Nowadays, colorectal cancer is one of the most prevalent diseases throughout the globe. Therefore, novel cancer treatment modalities are required to stop cancer. Thus, this paper aims to develop a novel drug delivery system (DDS) based on Chitosan (CS), polyamidoamine (PAMAM G4), and Nanoparticles (NP) for efficient delivery of sodium butyrate (NB) and Fe2O3 to SW480 colorectal cancer cells. Methods To do so, after characterizing the nanocarrier with FT-IR, DLS, TEM, and TGA, nanometric size (40-65 nm), high drug content (23% Fe2O3 and 3% NB), controlled NB release (4% within 2 h), and pH-sensitive NB release (35% within 2 h) were measured for CS-PAMAM-Fe2O3-NB. Result In biomedical tests, MTT assay indicated 10% (after 24 h), 8% (after 48 h), and 7% (after 72 h) cell viabilities for 200 nM concentration of CS-PAMAM-Fe2O3-NB nanocarrier on SW480 cells while pure NB did not have potential toxicity on cancer cells. IC50 determined for 25 nM after 24 h. qRT-PCR test indicated a 7-fold and 10-fold increase for Caspase9 and Bax apoptotic genes whereas 0.3-fold expression quantified for Bcl2 anti-apoptotic gene. Conclusion According to the obtained results, it can be concluded that the fabricated nanocarrier would be a potential DDS against colorectal cancer cells. The results of these biomedical tests have approved potential the ability of the synthesized DDS in the inhibition of colorectal cancer cells. High biocompatibility was shown in MSC normal cells which further verified the efficiency of CS-PAMAM-Fe2O3-NB.
dc.identifier.doi10.1186/s12876-025-04473-y
dc.identifier.issn1471-230X
dc.identifier.issue1
dc.identifier.orcid0000-0003-1104-4626
dc.identifier.pmid41466225
dc.identifier.scopus2-s2.0-105026144893
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1186/s12876-025-04473-y
dc.identifier.urihttps://hdl.handle.net/11486/8480
dc.identifier.volume25
dc.identifier.wosWOS:001651204500001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofBmc Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260420
dc.subjectPAMAM-Chitosan nanoparticles
dc.subjectFe2O3 nanoparticles
dc.subjectSodium butyrate
dc.subjectControlled drug release
dc.subjectColorectal cancer inhibition
dc.titleSodium butyrate entrapped chitosan-PAMAM for suppression of colorectal cancer cells
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu